NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Novartis ( NYSE:NVS )
Novartis AG ( NYSE:NVS ) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Ad hoc announcement pursuant to Art. 53 LR ...
Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today - Avidity Biosciences ( NASDAQ:RNA )
Avidity Biosciences ( NASDAQ:RNA ) has outperformed the market over the past 5 years by 6.63% on an annualized basis producing an average annual return of 19.41%. Currently, Avidity Biosciences has a market capitalization of $10.62 billion.
Looking Into Avidity Biosciences Inc's Recent Short Interest - Avidity Biosciences ( NASDAQ:RNA )
Avidity Biosciences Inc's ( NYSE:RNA ) short interest as a percent of float has fallen 49.24% since its last report. According to exchange reported data, there are now 10.50 million shares sold short, which is 7.02% of all regular shares that are available for trading.
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
Avidity Biosciences, Inc. ( RNA ) Reports Q3 Loss, Beats Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of -20.95% and +399.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. ( NYSE - WTRG ) , Cadence Bank ( NYSE - CADE ) , Avidity Biosciences, Inc. ( Nasdaq - RNA ) , Plymouth Industrial REIT, Inc. ( NYSE - PLYM )
BALA CYNWYD, Pa., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Ovid Therapeutics ( OVID ) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Avidity Biosciences Stock Soared This Week ( There's More to the Deal Than You Might Think )
Novartis is set to boost its developmental pipeline with this acquisition.
Analysts Estimate Avidity Biosciences, Inc. ( RNA ) to Report a Decline in Earnings: What to Look Out for
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
$1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today - Avidity Biosciences ( NASDAQ:RNA )
Avidity Biosciences ( NASDAQ:RNA ) has outperformed the market over the past 5 years by 5.48% on an annualized basis producing an average annual return of 20.87%. Currently, Avidity Biosciences has a market capitalization of $10.23 billion.
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders - Avidity Biosciences ( NASDAQ:RNA )
NEW YORK, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. ( NASDAQ:RNA ) to Novartis for $72.00 per share in cash is fair to Avidity shareholders.
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Avidity Biosciences ( RNA ) Moves 42.4% Higher: Will This Strength Last?
Avidity Biosciences (RNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday - Cadence Bank ( NYSE:CADE ) , Cadence Design Systems ( NASDAQ:CDNS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Jefferies cut Ramaco Resources Inc ( NASDAQ:METC ) price target from $45 to $33.
This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Cadence Bank ( NYSE:CADE ) , Boot Barn Holdings ( NYSE:BOOT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Seaport Global analyst Mitch Kummetz downgraded the rating for Boot Barn Holdings Inc ( ...
Why Dyne Therapeutics Stock Crushed the Market on Monday
Biotechs like it are clearly valuable to strategic acquirers.
Why Avidity Biosciences Stock Blasted 42% Higher Today
If all goes well, the company will be part of a much larger enterprise starting next year.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. ( NYSE - WTRG ) , Cadence Bank ( NYSE - CADE ) , Avidity Biosciences, Inc. ( Nasdaq - RNA ) , Plymouth Industrial REIT, Inc. ( NYSE - PLYM )
BALA CYNWYD, Pa., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Avidity Biosciences ( NASDAQ:RNA ) , Novartis ( NYSE:NVS )
Avidity Biosciences, Inc. ( NASDAQ:RNA ) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG ( NYSE:NVS ) , marking one of the largest biotech buyouts of the year. H.C.
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday - Strive ( NASDAQ:ASST ) , American Bitcoin ( NASDAQ:ABTC )
U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Monday. Shares of Janus Henderson Group plc ( NYSE:JHG ) rose sharply during Monday's session after the company confirmed receiving a non-binding takeover proposal from Trian Fund Management for $46 per share.
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday - Carpenter Technology ( NYSE:CRS ) , Booking Holdings ( NASDAQ:BKNG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stifel cut DraftKings Inc ( NASDAQ:DKNG ) price target from $51 to $50.
This Harley-Davidson Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Harley-Davidson ( NYSE:HOG ) , First BanCorp ( NYSE:FBP )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Why Is Avidity Biosciences Stock Skyrocketing Monday? - Avidity Biosciences ( NASDAQ:RNA ) , Novartis ( NYSE:NVS )
Avidity Biosciences, Inc. ( NASDAQ:RNA ) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG ( NYSE:NVS ) in a deal valued at $12 billion on a fully diluted basis. As per the deal, Avidity shareholders will receive $72.00 per share in cash at ...
Stock Market Today: Dow Jones, S&P 500 Futures Climb Ahead Of Busy Week On Wall Street-Novartis, Nucor, Waste Management In Focus - SPDR S&P 500 ( ARCA:SPY )
U.S. stock futures rose on Monday following Friday's positive moves. Futures of major benchmark indices were higher. Investors are eyeing multiple developments this week, which include the earnings report of five firms among the Magnificent 7 constituents.
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - American Resources ( NASDAQ:AREC ) , Strive ( NASDAQ:ASST )
Shares of Avidity Biosciences Inc ( NASDAQ:RNA ) rose sharply in pre-market trading after the company agreed to be acquired by Novartis AG ( NYSE:NVS ) . Holders of Avidity common stock will receive $72.00 per share in cash at closing, representing a premium of around 46% over Avidity's ...
RNA STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF AVIDITY BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS - Avidity Biosciences ( NASDAQ:RNA )
NEW YORK, Oct. 26, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. ( NASDAQ:RNA ) to Novartis for $72.00 per share in cash is fair to Avidity shareholders.
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
Ad hoc announcement pursuant to Art. 53 LR ...
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
Is Avidity Biosciences Inc Gaining or Losing Market Support? - Avidity Biosciences ( NASDAQ:RNA )
Avidity Biosciences Inc's ( NYSE:RNA ) short interest as a percent of float has fallen 6.71% since its last report. According to exchange reported data, there are now 20.75 million shares sold short, which is 14.33% of all regular shares that are available for trading.
Looking Into Avidity Biosciences's Recent Short Interest - Avidity Biosciences ( NASDAQ:RNA )
Avidity Biosciences's RNA short interest as a percent of float has risen 12.11% since its last report. According to exchange reported data, there are now 17.57 million shares sold short, which is 14.72% of all regular shares that are available for trading.
Crude Oil Rises 1%; Manufacturing Activity in New York Falls In September - Robo.ai ( NASDAQ:AIIO ) , aTyr Pharma ( NASDAQ:ATYR )
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.1% on Monday. The Dow traded up 0.06% to 45,856.77 while the NASDAQ rose 0.75% to 22,307.16. The S&P 500 also rose, gaining, 0.37% to 6,608.41. Consumer discretionary shares jumped by 1.9% on Monday.
IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday - Figure Technology ( NASDAQ:FIGR ) , Six Flags Entertainment ( NYSE:FUN )
U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Friday. Shares of IBEX Limited IBEX rose sharply during Friday's session after the company reported better-than-expected fourth-quarter financial results and issued FY26 sales guidance above estimates.
Nasdaq Jumps Over 150 Points; Kroger Earnings Top Estimates - Lovesac ( NASDAQ:LOVE ) , Kroger ( NYSE:KR )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 1.32% to 46,089.25 while the NASDAQ rose 0.72% to 22,044.49. The S&P 500 also rose, gaining, 0.80% to 6,584.57. Consumer discretionary shares jumped by 1.6% on ...
Why Oxford Industries Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Ekso Bionics Holdings ( NASDAQ:EKSO ) , CI&T ( NYSE:CINT )
Shares of Oxford Industries, Inc. OXM rose sharply in pre-market trading after the company reported better-than-expected second-quarter earnings results and raised its FY25 EPS guidance above estimates. Oxford Industries reported quarterly earnings of $1.26 per share, which beat the analyst ...
Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - CI&T ( NYSE:CINT ) , Enovix ( NASDAQ:ENVX )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday. Shares of Lovesac Co LOVE fell sharply in pre-market trading after the company posted results for its second quarter.
Avidity Drug Shows Yearlong Gains In Duchenne Muscular Dystrophy Trial - Avidity Biosciences ( NASDAQ:RNA )
Del-Zota raised dystrophin levels by up to 58% of normal and cut CK levels by over 80% at one year. Functional tests like stair climb and walk/run improved while natural history groups showed declines. Get the strategy to turn September's volatility into 10x trades → Avidity Biosciences, Inc.
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.
Clene Inc. ( CLNN ) Reports Q2 Loss, Misses Revenue Estimates
Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Mersana Therapeutics, Inc. ( MRSN ) Reports Q2 Loss, Lags Revenue Estimates
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics ( FATE ) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Avidity ( RNA ) Q2 Revenue Jumps 88%
Avidity Biosciences ( NASDAQ:RNA ) , a biotechnology firm developing RNA-targeted therapeutics for rare muscle diseases, reported its second-quarter 2025 results on August 7, 2025. The period featured sharply higher revenue ( GAAP ) at $3.8 million, well above the $1.49 million average analyst ...
Iovance Biotherapeutics ( IOVA ) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics, Inc. ( ARQT ) Reports Q2 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Quanta Announces Leadership Team Appointment and Highlights Clinical Program Progress
- 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership - - Enrollment initiated in dose expansion cohorts in Phase 1 clinical trial of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with KRASG12D-mutant pancreatic, ...
Veritex Holdings, Sequans Communications, Canaan And Other Big Stocks Moving Higher On Monday - DeFi Technologies ( NASDAQ:DEFT ) , Canaan ( NASDAQ:CAN )
U.S. stocks were lower, with the Dow Jones index falling around 0.1% on Monday. Shares of Veritex Holdings, Inc. VBTX rose sharply during Monday's session after announcing that Huntington Bancshares will acquire them for $1.9 billion. Veritex Holdings shares jumped 22.1% to $33.52 on Monday.
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial - Avidity Biosciences ( NASDAQ:RNA )
Del-Brax improved muscle strength, mobility, and quality of life in FSHD patients in early-stage trials. Avidity begins Phase 3 FORWARD trial as del-brax shows rapid biomarker reduction and strong safety profile. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology - Cytokinetics ( NASDAQ:CYTK )
Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field
